The content on this site is intended for healthcare professionals only
Dr Lavrov speaks with ecancertv at the IFHNOS 2016 session in Moscow about molecular genetics aiding in diagnosis and treatment of thyroid cancer.
He outlines the processes by which mutational aberrations can be detected, and how to cope with the wealth of data rendered by next-generation sequencing.
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Best practice in HRRm testing in patients with metastatic prostate cancer
Multiple myeloma in a resource constrained setting
Management of prostate cancer in Africa: Looking to the future
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania
Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
